Company Overview
Beta Bionics, Inc. operates as a commercial-stage medical device company dedicated to the design, development, and commercialization of solutions aimed at enhancing the health and quality of life for insulin-requiring individuals with diabetes. The company's primary product offering is the iLet Bionic Pancreas, an insulin delivery device specifically engineered for the treatment of type 1 diabetes. This entity functions within the broader Healthcare sector and the specialized Medical Devices industry, a classification that signifies its focus on tangible therapeutic equipment rather than pharmaceuticals or services. The company currently maintains a market capitalization of $501.96M and reported trailing twelve-month revenue of $100.25M while employing a workforce of 420 individuals. These financial metrics collectively indicate that Beta Bionics holds a mid-cap position in the medical device landscape, suggesting it has achieved a level of market recognition that warrants significant institutional attention but remains distinct from large-cap peers with revenues in the multi-billion dollar range.
Financial Health
Beta Bionics, Inc. reported revenue of $100.25M for the trailing twelve months, yet this top-line figure masks a net income loss of $73,200,000 and an EBITDA of $-70,108,000. The substantial gap between the positive revenue of $100.25M and the negative net income reveals a cost structure where operating expenses, likely driven by research and development or commercialization efforts, exceed total earnings before interest and taxes. The company generated a free cash flow of $-40,903,624, which indicates that its capital expenditures and working capital requirements currently exceed its cash generation from operations, a common characteristic for growth-stage medical device firms. Despite these cash outflows, the company holds a cash balance of $219.12M against total debt of $7.30M, resulting in a debt-to-equity ratio of 2.54. This liquidity position suggests the balance sheet is heavily reliant on equity financing rather than debt, though the high debt-to-equity ratio warrants scrutiny regarding long-term leverage management. The current ratio stands at 8.66, a metric that signals robust short-term liquidity, as current assets are more than eight times current liabilities, providing ample buffer for immediate obligations. Return on Equity is recorded at -40.3% and Return on Assets at -18.7%, figures that demonstrate the company is currently destroying value per unit of capital invested rather than generating returns for shareholders or asset holders.
Valuation Assessment
Valuation metrics for Beta Bionics, Inc. reflect its pre-profitability status, with a trailing P/E ratio of N/A due to negative earnings and a forward P/E of -5.84. The divergence between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing in a future path to profitability that has not yet been realized in historical earnings data. The price-to-book ratio is 1.74, indicating that the market values the company's equity at a 74% premium over its net asset book value, suggesting investors anticipate future growth potential that is not yet reflected in the balance sheet. Alternative valuation multiples such as the price-to-sales ratio of 5.01 and an EV/EBITDA of -4.14 provide context for investors analyzing revenue-based valuations, as the negative EV/EBITDA confirms the absence of positive earnings before interest, taxes, depreciation, and amortization. The stock has traded within a 52-week range bounded by a high of $32.71 and a low of $8.89. Without a specific current share price provided in the facts to calculate the exact percentage deviation, the valuation range indicates significant volatility, with the stock capable of moving from levels near the 52-week low to those approaching the high. The beta value is listed as N/A, meaning that standard volatility relative to the broader market index cannot be quantified with the available data points.
Growth & Income
Revenue growth for the company is recorded at 57.1% year-over-year, while earnings growth is N/A due to the lack of positive net income in the prior period. The fact that revenue is growing significantly while earnings remain negative implies that the company is prioritizing top-line expansion and market penetration over immediate profitability, a strategy typical for commercial-stage medical device innovators. As a non-dividend payer, Beta Bionics, Inc. does not distribute cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This zero payout ratio is sustainable given the negative earnings, as the company retains all generated cash to fund operations, R&D, and the commercialization of its iLet Bionic Pancreas technology rather than paying dividends. The overall growth and income profile is defined by aggressive revenue expansion in the diabetes treatment space with no current income distribution, positioning the stock purely as a growth vehicle dependent on future operational success.